Gabriel Schwartz, MSN, NP, explains how mechanisms of action determine the safety of systemic treatments in metastatic colorectal cancer post chemotherapy.

Q3 2025 Earnings Call Transcript November 7, 2025 Operator: Good afternoon, everyone. Thank you for standing by. Welcome to ...

WOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ...

The DESTINY-Breast11 trial showed in patients with high-risk HER2-positive early breast cancer that the ADC followed by ...

Pfizer Inc. ( PFE) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology November 10, 2025 8:30 AM EST ...

Immunocore reports third quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $103.7 million in ...

Detailed price information for Summit Therapeu ADR (SMMT-Q) from The Globe and Mail including charting and trades.

Disease modifying mechanism of action: short treatment course results in significant and durable clinical response in psoriasis patients si-544 is the first highly potent and selective Kv1.3 blocker ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

The brain does not need its sophisticated cortex to interpret the visual world. A new study published in PLOS Biology ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...